Rigel Pharmaceuticals

We are utilizing our deep understanding of genetic drivers and adaptive resistance mechanisms in cancer, coupled with robust drug discovery and medicinal chemistry capabilities, to build a portfolio of compounds that inhibit critical signaling nodes within the RAS and associated pathways, such as the mTOR pathway. Our cohesive approach of focusing on targets within these signaling pathways underpins our clinical strategy of exploring mechanism-based dosing paradigms and in-pathway combinations to optimize treatment for cancer patients. Our most advanced product candidate is RMC-4630, a clinical-stage drug candidate that potently and selectively inhibits SHP2, a central node in the RAS signaling pathway. In collaboration with our partner, Sanofi, we are evaluating RMC-4630 in a multi-cohort Phase 1/2 clinical program for a range of tumor types featuring specific oncogenic mutations. Additionally, we are developing a portfolio of mutant-selective RAS inhibitors that we believe are the first potent, selective, cell-active inhibitors of the active, GTP-bound form of RAS, or RAS(ON).

We are building a leading biotechnology company through the development of novel and differentiated targeted medicines in cancer and fibrotic disease, and the emerging area of cancer-associated fibrosis, where we see the opportunity to be best-in-class, or first-in-class. Redx is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, targeted medicines for the treatment of fibrotic disease, cancer and the emerging area of cancer-associated fibrosis. Our ambition is to create world leading medicines that will transform patients’ lives, by delivering better medicines faster. Deliver Focus our differentiated, targeted small molecules towards commercially attractive markets in which we believe we can be successful. At Redx, our ambition is to create world leading medicines that will transform patients’ lives, by delivering better medicines faster. The securities referred to herein may not be offered, sold, resold, taken up, transferred, delivered or distributed, directly or indirectly, within, into or in the United States of America or any US territory, Australia, Canada, Japan, the Republic of South Africa or any other Restricted Jurisdiction except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States or such other jurisdiction. There will be no public offer of securities in the United States or any other Restricted Jurisdiction. Zelasudil is a clinical stage, highly selective and orally available ROCK2 inhibitor being developed for the treatment of idiopathic pulmonary fibrosis and fibrotic diseases.

The company is a significant investor in two clinical stage oncology companies, Cornerstone Pharmaceuticals, Inc., and LipoMedix Pharmaceuticals Ltd., and is seeking opportunities to invest, acquire or in-license additional therapeutic assets which address high unmet medical needs. Rafael Holdings, Inc., (NYSE: RFL) is a fast-growing company focused on the discovery and development of novel oncological therapeutics to improve and extend the lives of patients through a wholly-owned and controlled portfolio of companies. Rafael is committed to providing reasonable accommodations for qualified individuals with disabilities and disabled veterans in our job application procedures.

SignalRx is a privately owned biopharmaceutical company, with operations in San Diego, California and Omaha, Nebraska, that is pioneering the development of a new class of effective cancer targeted therapeutics. We are committed to the development of oncology products that significantly improve the lives of pediatric and adult cancer patients. The founders of SignalRx are inventors of the second PI3K inhibitor to enter the clinic and are leaders capitalizing on selective multi-target single small-molecule drug design and development. SignalRx is pursuing unique programs targeting the combined inhibition of key pathways involved in cancer proliferation, metastasis, angiogenesis as well as immuno-oncology (e.g., BTK, BRD4, CDK, PI3K, MYC).

We are keenly focused on leveraging the body’s natural pathways to treat cancer and its related conditions. FibroGen and our partner AstraZeneca filed a supplemental new drug application with the China Health Authority for roxadustat in patients with chemotherapy-induced anemia and expect an approval decision in mid-2024. We are developing products with the potential to change lives. We are dedicated to responsibly developing groundbreaking therapies for serious and life-threatening diseases. We accelerate the delivery of innovative treatments that operate at the cutting edge of cancer research. Pamrevlumab is a potential first-in-class human monoclonal antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF), a common factor in proliferative disorders and certain cancer cell types. FG-3246 is a potential first-in-class fully human antibody-drug conjugate (ADC), in-licensed from Fortis and being developed with FibroGen for metastatic castration-resistant prostate cancer and other tumor types.

We are leaders in the field of RSK inhibition and recently completed a first-in-human clinical trial with our lead candidate, PMD-026, in breast cancer patients. Our vision is to deliver precision medicine based on the genetic composition of a person’s tumor, creating better solutions for cancer treatments and improving the lives of patients. Our patented cancer compounds position us in the lead to streamline our product to market through patient selection using a companion diagnostic to identify cancer patients who will optimally benefit from RSK targeted therapies. We focus on patented RSK inhibitors and companion diagnostics for cancers, including those that develop in the brain, breast, colon and prostate.